TD Cowen Affirms Buy Rating on Cardinal Health

Neha Gupta

Mon, Jun 16, 2025, 9:50 AM 1 min read

Cardinal Health (NYSE:CAH) is one of the best 52-week high stocks to buy, according to analysts. On June 10, analysts at TD Cowen reiterated a Buy rating and maintained a price target of $162 on the stock.

A close-up of a person's hand holding a bottle of pharmaceuticals.

The analysts expect the company to increase its long-term pharmaceutical profit guidance from 5% to 7% from a previous guidance of 4% and 6%. Cardinal Health is also expected to introduce preliminary adjusted earnings per share guidance in the range of $9.15 to $9.45.

TD Cowen analyst also expects Cardinal Health to provide insights on how other segment businesses will contribute 18% of adjusted operating income. The company has entered into a distribution agreement with Citious Oncology to support the launch of FDA-approved immunotherapy LYMPHIR.

Cardinal Health (NYSE:CAH) is a global healthcare company that distributes pharmaceuticals and specialty products. It also manufactures and distributes medical and laboratory products.

While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Popular AI Stocks to Avoid Now and Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential.

Disclosure: None.